John Francis Seymour

机构：The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre · ORCID：0000-0003-2188-6835

发表论文 999 篇 · 总被引 56986 次 · h-index 112

代表论文

• Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 27)
• Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study (2025 · Blood · 被引 7)
• Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study (2025 · Blood · 被引 5)
• FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma (2025 · Journal of Clinical Oncology · 被引 4)
• Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant (2026 · Blood · 被引 3)
• Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma (2025 · Blood Advances · 被引 2)